Exelixis (NASDAQ:EXEL) CFO Christopher Senner Sells 34,901 Shares

Posted by Brenda Bartman on May 20th, 2026

Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) CFO Christopher Senner sold 34,901 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $50.00, for a total transaction of $1,745,050.00. Following the transaction, the chief financial officer owned 952,317 shares of the company’s stock, valued at approximately $47,615,850. This represents a 3.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Exelixis Price Performance

EXEL opened at $48.67 on Wednesday. Exelixis, Inc. has a fifty-two week low of $33.76 and a fifty-two week high of $51.63. The firm has a market capitalization of $12.23 billion, a price-to-earnings ratio of 16.17, a PEG ratio of 1.05 and a beta of 0.38. The company’s 50 day moving average price is $44.62 and its two-hundred day moving average price is $43.64.

Exelixis (NASDAQ:EXEL – Get Free Report) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.12. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm had revenue of $610.81 million for the quarter, compared to analyst estimates of $607.51 million. During the same period in the previous year, the firm posted $0.55 EPS. The company’s revenue for the quarter was up 10.0% compared to the same quarter last year. As a group, equities research analysts predict that Exelixis, Inc. will post 3.15 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Motiv8 Investments LLC acquired a new position in shares of Exelixis during the 4th quarter valued at $26,000. Anchor Investment Management LLC lifted its position in shares of Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 500 shares during the period. Cassaday & Co Wealth Management LLC acquired a new position in shares of Exelixis during the 1st quarter valued at $27,000. Acumen Wealth Advisors LLC acquired a new position in shares of Exelixis during the 4th quarter valued at $29,000. Finally, Root Financial Partners LLC acquired a new position in shares of Exelixis during the 3rd quarter valued at $28,000. Institutional investors and hedge funds own 85.27% of the company’s stock.

Analyst Upgrades and Downgrades

EXEL has been the topic of a number of research reports. Weiss Ratings reissued a “buy (b)” rating on shares of Exelixis in a report on Thursday, January 22nd. Truist Financial raised shares of Exelixis to a “strong-buy” rating in a report on Monday, April 27th. HC Wainwright upped their price objective on shares of Exelixis from $54.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Morgan Stanley upped their price objective on shares of Exelixis from $49.00 to $50.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Royal Bank Of Canada reduced their price objective on shares of Exelixis from $46.00 to $43.00 and set a “sector perform” rating on the stock in a research note on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $47.35.

Get Our Latest Stock Report on EXEL

About Exelixis

(Get Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.